Literature DB >> 20478857

Right ventricular absolute myocardial blood flow in complex congenital heart disease.

Tobias Rutz1, Stefano F de Marchi, Markus Schwerzmann, Rolf Vogel, Christian Seiler.   

Abstract

OBJECTIVE: A consequence in patients with d-transposition of the great arteries (d-TGA) and tetralogy of Fallot (TOF) is right ventricular hypertrophy (RVH) and right ventricular failure. Myocardial contrast echocardiography (MCE) permits the determination of the myocardial microvascular density reflected by the relative myocardial blood volume (rBV; ml/ml). This study was conducted to elucidate the relationship between RVH and myocardial microvascular changes by quantitative MCE in patients with d-TGA and TOF.
METHODS: Three groups of individuals were included in the study: 22 patients with d-TGA, 18 patients with TOF and 22 healthy individuals (controls). MCE was performed at rest and during adenosine-induced hyperaemia. rBV and myocardial blood flow (MBF; ml/min per gram) were derived from steady state and refill sequences of ultrasound contrast agent.
RESULTS: Hyperaemic septal rBV differed significantly between the groups and was highest in controls: d-TGA 0.141+/-0.060 ml/ml, TOF 0.134+/-0.080 ml/ml, controls 0.189+/-0.074 ml/ml, p=0.005. Myocardial blood flow reserve (MBFR), that is the ratio of hyperaemic to baseline MBF, differed significantly between the groups and was lowest in d-TGA (2.68+/-1.13) versus TOF (3.37+/-1.57) and controls (4.22+/-1.17, p=0.001). Hyperaemic septal rBV, MBF and MBFR showed a significant correlation with right ventricular systolic function as determined by tricuspid annular plane systolic excursion.
CONCLUSIONS: Right ventricular myocardial microvascular density of the septal wall in d-TGA and TOF patients with RVH due to pressure and/or volume overload is reduced. This appears to be related to a reduced myocardial perfusion reserve and impaired right ventricular systolic function.

Entities:  

Mesh:

Year:  2010        PMID: 20478857     DOI: 10.1136/hrt.2009.191718

Source DB:  PubMed          Journal:  Heart        ISSN: 1355-6037            Impact factor:   5.994


  7 in total

1.  Assessment of coronary flow reserve in the coronary sinus by cine 3T-magnetic resonance imaging in young adults after surgery for tetralogy of Fallot.

Authors:  Jochem Cuypers; Elisabeth Leirgul; Stig Samnøy; Terje H Larsen; Ansgar Berg; Ingram Schulze-Neick; Gottfried Greve
Journal:  Pediatr Cardiol       Date:  2011-09-07       Impact factor: 1.655

Review 2.  Management of Heart Failure in Adult Congenital Heart Disease.

Authors:  Aarthi Sabanayagam; Omer Cavus; Jordan Williams; Elisa Bradley
Journal:  Heart Fail Clin       Date:  2018-08-20       Impact factor: 3.179

Review 3.  Heart failure in single right ventricle congenital heart disease: physiological and molecular considerations.

Authors:  Anastacia M Garcia; Jonathan-Thomas Beatty; Stephanie J Nakano
Journal:  Am J Physiol Heart Circ Physiol       Date:  2020-02-28       Impact factor: 4.733

4.  Overview of adult congenital heart transplants.

Authors:  Roosevelt Bryant; David Morales
Journal:  Ann Cardiothorac Surg       Date:  2018-01

Review 5.  Clinical applications of radionuclide imaging in the evaluation and management of patients with congenital heart disease.

Authors:  Sara L Partington; Anne Marie Valente; Michael Landzberg; Frederick Grant; Marcelo F Di Carli; Sharmila Dorbala
Journal:  J Nucl Cardiol       Date:  2015-07-01       Impact factor: 5.952

6.  Plasma Levels of High Sensitivity Cardiac Troponin T in Adults with Repaired Tetralogy of Fallot.

Authors:  Clare T M Lai; Sophia J Wong; Janice J K Ip; Wai-keung Wong; Kwong-cheong Tsang; Wendy W M Lam; Yiu-fai Cheung
Journal:  Sci Rep       Date:  2015-09-11       Impact factor: 4.379

7.  Three-dimensional alignment of microvasculature and cardiomyocytes in the developing ventricle.

Authors:  Maryse Lapierre-Landry; Hana Kolesová; Yehe Liu; Michiko Watanabe; Michael W Jenkins
Journal:  Sci Rep       Date:  2020-09-11       Impact factor: 4.379

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.